Database

Startups

Main Industry
Health Care
Main Product/Service
1. Cell Therapy
2. Clinical trial
3. MCRcIR
4. MiSaverR
Founded Year
2011
Unified Business No.
53523105
Status
Active
Number of Employees
0
Total Paid-in Capital
200,544,220 (NT$)
Location of Company
Taiwan , Tainan City
Website
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE."
Introduction
HONYA Medical is a cutting-edge stem cell pharmaceutical company dedicated to developing advanced regenerative therapies. Focused on combating cardiovascular diseases and other degenerative conditions, HONYA creates state-of-the-art stem cell products that are ethically sourced and manufactured under strict GTP/GMP standards. Their pioneering technologies enable the cultivation, modification, and use of stem cells to repair and regenerate tissues, offering new hope for patients worldwide. With a mission to redefine health through innovation, HONYA is at the forefront of transforming the future of medicine.



More ↓

Similar Companies

TRUST BIO-SONICS INC.

1. Ultrasound Imaging Agents
2. Ultrasound-Mediated Targeted Delivery

TAIWAN BIO THERAPEUTICS INC.

Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppressants for autoimmune disease treatment and transplant rejection prevention./Utilizing the FAST CGT platform enhance therapeutic efficacy, durability, and precision of MSC therapies for treating inflammatory and ischemic diseases/Integrating cell therapy R&D and clinical applications through the FAST CGT platform to accelerate the development and commercialization

Acura NanoMedicine Corporation

1. Out-licensing of innovative drug products, including the AN-8 series, a novel therapy designed to reverse cancer drug resistance, and other pharmaceuticals.
2. Utilizing proprietary technology platforms — (1) the HTPVAC drug development platform and (2) three nanomedicine delivery platforms to engage in joint new drug development and licensing partnerships